This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

Exploring the mHSPC patient journey

An interactive case study presented at P3 Prostate Cancer Forum 2025

P3 background - Article

Dive into a visual case study that explores a highly requested patient scenario. This resource is designed to highlight the complexities of treatment decision-making in high-risk metastatic hormone-sensitive prostate cancer (mHSPC), backed by essential data that informs clinical choices.

DOWNLOAD THE CASE STUDY

Evidence-Based Insights for Treatment Decision-Making in mHSPC

Join Dr. Amarnath Challapalli and Dr. Hilary Glen as they present a comprehensive overview of randomised controlled trial (RCT) and real-world evidence (RWE) data. Discover the latest insights from the recent UK Consensus Publication that support informed treatment strategies for mHSPC. 

NUBEQA  (darolutamide) Prescribing Information

Addressing the “Older Patient” Conundrum

Prof. Alison Birtle and Dr. Mark Prentice tackle a critical clinical challenge: determining the appropriate application of triple therapy in older patients with mHSPC. Gain valuable insights into this complex decision-making process.

NUBEQA  (darolutamide) Prescribing Information

Speakers

  • Professor Fred Saad, Urologist & Oncologist, The University of Montreal Hospital Center

    Professor Alison Birtle, Consultant Oncologist, Lancashire Teaching Hospitals NHS Trust

    Dr Pasquale Rescigno, Senior Lecturer, Newcastle University

    Dr Hilary Glen, Consultant Medical Oncologist, Beatson West of Scotland Cancer Centre

    Dr Amarnath Challapalli, Consultant Clinical Oncologist and Clinical Director, Bristol Haematology and Oncology Centre

    Dr Mark Prentice, Consultant Clinical Oncologist, Royal Free London NHS Foundation Trust

Finding consensus on utilising triplet therapy in mHSPC p...
Discussing triplet therapy in low-burden metastatic hormone-sensitive prostate cancer (mHSPC).
PP-NUB-GB-2383, June 2025
Resources to support prostate cancer patients
A focus on drug-to-drug interactions, managing risk and navigating around psychosexual health.
PP-NUB-GB-2385, June 2025
P3 Prostate Cancer Forum 2025
Join us as we recap the P3 Prostate Cancer Forum held on May 16-17, 2025.
PP-NUB-GB-2381, June 2025

PP-NUB-GB-2382, June 2025